| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This short N-terminal fragment lacks the C-terminal residues required for high-affinity binding to AT1 or AT2 receptors. It is not an active receptor ligand but may interact nonspecifically or serve as an ACE substrate.
|
|---|---|
| ln Vitro |
As a short peptide fragment, it does not exhibit significant receptor binding activity or functional signaling in standard cell-based assays. It may be used to study enzymatic cleavage patterns or as a peptide stability control.
|
| ln Vivo |
This peptide lacks intrinsic vasoactive properties. It is inactive in blood pressure regulation models and does not produce the classic effects of angiotensin II, such as vasoconstriction or aldosterone release.
|
| Enzyme Assay |
Receptor binding studies typically use membrane preparations from tissues or cells expressing AT1 or AT2 receptors, incubated with radiolabeled angiotensin II. This peptide serves as a control to demonstrate binding specificity. Enzyme assays with ACE can measure its cleavage.
|
| Cell Assay |
The peptide can be added to cell cultures expressing ACE to monitor enzymatic conversion to smaller fragments via HPLC or mass spectrometry. It is not typically used for functional readouts like calcium flux or cAMP accumulation.
|
| Animal Protocol |
In animal models, this peptide is primarily administered for pharmacokinetic studies to track peptide metabolism and degradation. Blood samples are collected at various time points and analyzed by LC-MS/MS to quantify the peptide and its metabolites.
|
| ADME/Pharmacokinetics |
Like other small peptides, it is rapidly degraded by peptidases in plasma and tissues, resulting in a very short half-life (likely less than a few minutes). It is cleared primarily via hydrolysis and renal excretion.
|
| Toxicity/Toxicokinetics |
No significant toxicity is reported for this peptide fragment in standard research applications. It exhibits low biological activity and is considered safe when handled according to standard laboratory safety protocols for peptides.
|
| References | |
| Additional Infomation |
This peptide is a minimal fragment of the angiotensin II sequence and is often used as a negative control or metabolite marker in experiments involving the RAAS. It is not intended for clinical use. Strictly a research-grade biochemical.
|
| Molecular Formula |
C32H49F3N8O11
|
|---|---|
| Molecular Weight |
778.77
|
| Related CAS # |
Angiotensin I/II (1-5);58442-64-1
|
| Sequence |
Asp-Arg-Val-Tyr-IleDRVYI
|
| SequenceShortening |
DRVYI
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~20 mg/mL (~25.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.67 mg/mL (0.86 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (6.7 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2841 mL | 6.4204 mL | 12.8408 mL | |
| 5 mM | 0.2568 mL | 1.2841 mL | 2.5682 mL | |
| 10 mM | 0.1284 mL | 0.6420 mL | 1.2841 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
